Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Analysts at HC Wainwright lifted their FY2030 earnings estimates for shares of Pyxis Oncology in a research note issued on Thursday, September 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.79 for the year, up from their prior forecast of $0.76. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.21) per share.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05).
Get Our Latest Stock Report on PYXS
Pyxis Oncology Trading Down 2.9%
Shares of Pyxis Oncology stock opened at $3.33 on Monday. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55. The stock has a market cap of $277.76 million, a PE ratio of -2.36 and a beta of 1.34. The company has a 50-day moving average of $3.06 and a two-hundred day moving average of $2.27.
Institutional Investors Weigh In On Pyxis Oncology
A number of large investors have recently bought and sold shares of PYXS. J. Derek Lewis & Associates Inc. acquired a new position in shares of Pyxis Oncology in the fourth quarter worth $61,000. Atle Fund Management AB acquired a new stake in shares of Pyxis Oncology during the fourth quarter valued at $710,000. 683 Capital Management LLC boosted its stake in shares of Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after acquiring an additional 366,910 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after purchasing an additional 160,300 shares in the last quarter. Institutional investors and hedge funds own 39.07% of the company’s stock.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company focused on developing therapies for patients with cancer. The company’s approach is centered on creating antibody-based medicines designed to selectively target tumor cells or the tumor microenvironment while delivering therapeutic activity intended to improve cancer treatment outcomes.
Pyxis Oncology’s pipeline has included PYX-201, an antibody-drug conjugate designed to target extra-domain B fibronectin, a protein associated with the tumor microenvironment, and PYX-106, an investigational antibody targeting SIGLEC-15, an immune-regulatory protein expressed in several cancers.
Read More
- Five stocks we like better than Pyxis Oncology
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
